NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
14/01/2025
Voltar para busca
Dado oficial do USPTO
GENOMADIX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
GENOMADIX
ST13
US500000097978761Classe
1, 5, 9, 10
Pedido
97978761
Registro
7647631
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
55
Atualização mais recente
14/01/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 9, 10
Data de depósito
13/10/2021
Data de registro
14/01/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
14/01/2025
Última transação
14/01/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Primeiro uso
30/09/2021
Primeiro uso no comércio
31/07/2023
Código do desenho
4
Tipo de titular
99
Localização do titular
Kanata, Ontario, CA
Examinador
RIBAUDO, MICHELLE
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Genomadix Inc.
Representantes
Sara M. Bauer Womble Bond Dickinson (US) LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 9Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Diagnostic reagents for medical and scientific research purposesnot for medical use
Classe 5
Clinical diagnostic reagents for medical use; diagnostic biomarker reagents for medical purposes; diagnostic reagents for clinical medical laboratory use; diagnostic reagents for medical diagnostic use; diagnostic reagents for medical laboratory use; medical diagnostic reagents; medical diagnostic reagents and assays for testing of body fluid; reagents for use in medical genetic testing; swabs for medical purposes
Classe 9
Biomedical diagnostic apparatusfood and water safety testing for environmental monitoring; biomedical diagnostic apparatusmolecular diagnostic device used for nucleic acid testinginfectious disease testinggenetic testingdrug response testing for environmental monitoring for research purposes; biomedical devices in the nature of cartridges for loading biological samples for use in molecular diagnostic devices other than for medical use; testing sample collection equipmentswabs for obtaining biological samples from subjects for research purposes
Classe 10
Biomedical diagnostic apparatusmolecular diagnostic device used for nucleic acid testinginfectious disease testinggenetic testingdrug response testing for medical monitoring purposes; biomedical diagnostic devices in the nature of cartridges for loading biological samples for use in molecular diagnostic devices for medical purposes; medical devices for obtaining body fluid samples in the nature of testing sample collection equipment comprised of swabs for obtaining biological samples from subjects for biomedical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
55 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
14/01/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26/11/2024
PUBO
PUBLISHED FOR OPPOSITION
26/11/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/11/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/11/2024
IUAA
USE AMENDMENT ACCEPTED
01/11/2024
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
30/10/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
23/10/2024
GNSL
LETTER OF SUSPENSION E-MAILED
23/10/2024
CNSL
SUSPENSION LETTER WRITTEN
23/10/2024
ALIE
ASSIGNED TO LIE
22/10/2024
DPCC
DIVISIONAL PROCESSING COMPLETE
04/09/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/08/2024
DOCK
ASSIGNED TO EXAMINER
25/07/2024
IUAF
USE AMENDMENT FILED
17/06/2024
DRRR
DIVISIONAL REQUEST RECEIVED
17/06/2024
EAAU
TEAS AMENDMENT OF USE RECEIVED
17/06/2024
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
17/06/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/05/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/05/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
30/05/2024
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
20/03/2024
GNSI
INQUIRY TO SUSPENSION E-MAILED
20/03/2024
CNSI
SUSPENSION INQUIRY WRITTEN
20/03/2024
DOCK
ASSIGNED TO EXAMINER
20/03/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
26/02/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/12/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/12/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/12/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/12/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/12/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
24/08/2023
GNSL
LETTER OF SUSPENSION E-MAILED
24/08/2023
CNSL
SUSPENSION LETTER WRITTEN
24/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/08/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/08/2023
ALIE
ASSIGNED TO LIE
16/08/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
05/04/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
03/04/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
03/04/2023
CNSI
SUSPENSION INQUIRY WRITTEN
03/04/2023
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
30/03/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
27/08/2022
GNSL
LETTER OF SUSPENSION E-MAILED
27/08/2022
CNSL
SUSPENSION LETTER WRITTEN
27/08/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
17/08/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/08/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/08/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
22/07/2022
GNRT
NON-FINAL ACTION E-MAILED
22/07/2022
CNRT
NON-FINAL ACTION WRITTEN
22/07/2022
DOCK
ASSIGNED TO EXAMINER
19/07/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/11/2021
NWAP
NEW APPLICATION ENTERED
16/10/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace GENOMADIX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.